Molecular profiling of cancer - The future of personalized cancer medicine: A primer on cancer biology and the tools necessary to bring molecular testing to the clinic

Thomas Stricker, Daniel V.T. Catenacci, Tanguy Lim Seiwert

Research output: Contribution to journalArticle

Abstract

Cancers arise as a result of an accumulation of genetic aberrations that are either acquired or inborn. Virtually every cancer has its unique set of molecular changes. Technologies have been developed to study cancers and derive molecular characteristics that increasingly have implications for clinical care. Indeed, the identification of key genetic aberrations (molecular drivers) may ultimately translate into dramatic benefit for patients through the development of highly targeted therapies. With the increasing availability of newer, more powerful, and cheaper technologies such as multiplex mutational screening, next generation sequencing, array-based approaches that can determine gene copy numbers, methylation, expression, and others, as well as more sophisticated interpretation of high-throughput molecular information using bioinformatics tools like signatures and predictive algorithms, cancers will routinely be characterized in the near future. This review examines the background information and technologies that clinicians and physicianscientists will need to interpret in order to develop better, personalized treatment strategies.

Original languageEnglish (US)
Pages (from-to)173-185
Number of pages13
JournalSeminars in oncology
Volume38
Issue number2
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

Fingerprint

Precision Medicine
Technology
Neoplasms
Gene Dosage
Computational Biology
Methylation
Molecular Biology
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Molecular profiling of cancer - The future of personalized cancer medicine : A primer on cancer biology and the tools necessary to bring molecular testing to the clinic. / Stricker, Thomas; Catenacci, Daniel V.T.; Lim Seiwert, Tanguy.

In: Seminars in oncology, Vol. 38, No. 2, 01.04.2011, p. 173-185.

Research output: Contribution to journalArticle

@article{9ebf29d6551a4e75ac3f101131b86014,
title = "Molecular profiling of cancer - The future of personalized cancer medicine: A primer on cancer biology and the tools necessary to bring molecular testing to the clinic",
abstract = "Cancers arise as a result of an accumulation of genetic aberrations that are either acquired or inborn. Virtually every cancer has its unique set of molecular changes. Technologies have been developed to study cancers and derive molecular characteristics that increasingly have implications for clinical care. Indeed, the identification of key genetic aberrations (molecular drivers) may ultimately translate into dramatic benefit for patients through the development of highly targeted therapies. With the increasing availability of newer, more powerful, and cheaper technologies such as multiplex mutational screening, next generation sequencing, array-based approaches that can determine gene copy numbers, methylation, expression, and others, as well as more sophisticated interpretation of high-throughput molecular information using bioinformatics tools like signatures and predictive algorithms, cancers will routinely be characterized in the near future. This review examines the background information and technologies that clinicians and physicianscientists will need to interpret in order to develop better, personalized treatment strategies.",
author = "Thomas Stricker and Catenacci, {Daniel V.T.} and {Lim Seiwert}, Tanguy",
year = "2011",
month = "4",
day = "1",
doi = "10.1053/j.seminoncol.2011.01.013",
language = "English (US)",
volume = "38",
pages = "173--185",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Molecular profiling of cancer - The future of personalized cancer medicine

T2 - A primer on cancer biology and the tools necessary to bring molecular testing to the clinic

AU - Stricker, Thomas

AU - Catenacci, Daniel V.T.

AU - Lim Seiwert, Tanguy

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Cancers arise as a result of an accumulation of genetic aberrations that are either acquired or inborn. Virtually every cancer has its unique set of molecular changes. Technologies have been developed to study cancers and derive molecular characteristics that increasingly have implications for clinical care. Indeed, the identification of key genetic aberrations (molecular drivers) may ultimately translate into dramatic benefit for patients through the development of highly targeted therapies. With the increasing availability of newer, more powerful, and cheaper technologies such as multiplex mutational screening, next generation sequencing, array-based approaches that can determine gene copy numbers, methylation, expression, and others, as well as more sophisticated interpretation of high-throughput molecular information using bioinformatics tools like signatures and predictive algorithms, cancers will routinely be characterized in the near future. This review examines the background information and technologies that clinicians and physicianscientists will need to interpret in order to develop better, personalized treatment strategies.

AB - Cancers arise as a result of an accumulation of genetic aberrations that are either acquired or inborn. Virtually every cancer has its unique set of molecular changes. Technologies have been developed to study cancers and derive molecular characteristics that increasingly have implications for clinical care. Indeed, the identification of key genetic aberrations (molecular drivers) may ultimately translate into dramatic benefit for patients through the development of highly targeted therapies. With the increasing availability of newer, more powerful, and cheaper technologies such as multiplex mutational screening, next generation sequencing, array-based approaches that can determine gene copy numbers, methylation, expression, and others, as well as more sophisticated interpretation of high-throughput molecular information using bioinformatics tools like signatures and predictive algorithms, cancers will routinely be characterized in the near future. This review examines the background information and technologies that clinicians and physicianscientists will need to interpret in order to develop better, personalized treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=79952943956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952943956&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2011.01.013

DO - 10.1053/j.seminoncol.2011.01.013

M3 - Article

C2 - 21421108

AN - SCOPUS:79952943956

VL - 38

SP - 173

EP - 185

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2

ER -